ライフサイエンスコーパス: IL-2 receptor

1 L-2) that targets tumor cells expressing the IL-2 receptor.

2 ted lymphocytes expressing the high-affinity IL-2 receptor.

3 lymphocytes depends on signaling through the IL-2 receptor.

4 mechanism that blocks signaling through the IL-2 receptor.

5 e at concentrations equal to the K(D) of the IL-2 receptor.

6 ithout affecting their surface expression of IL-2 receptor.

7 sponses despite strong signaling through the IL-2 receptor.

8 urface expression of CD25, the high-affinity IL-2 receptor.

9 sents the high-affinity alpha-subunit of the IL-2 receptor.

10 terleukin-2 (IL-2) via ectopically expressed IL-2 receptors.

11 usly expressed cytokine receptors, including IL-2 receptors.

12 signals emanating from exogenously expressed IL-2 receptors.

13 n is an essential component of high-affinity IL-2 receptors.

14 equent decreased gene expression of IL-2 and IL-2 receptors.

15 common gamma-chain functional high-affinity IL-2 receptors.

16 ting T cell functions through interleukin-2 (IL-2) receptors.

17 mplex class II antigens (>75%), interleukin (IL) 2 receptor (5-10%), and staining for IL-2 (approxima

18 antigen 4 (CTLA4), interleukin (IL)-2/IL-21, IL-2 receptor A (IL-2RA; CD25) and Eos (also known as Ik

19 Daclizumab is a humanized mAb that binds the IL-2 receptor a subunit (IL-2R a or CD25) and prevents I

20 the alloantigen Thy-1 (CD90), interleukin 2 (IL-2) receptor a-chain (CD25), IL-7 receptor a-chain (CD

21 Blocking the common gamma c of IL-2 receptor, a shared essential signaling component by

22 These results demonstrate that the IL-2 receptor activation, among other early events, lead

23 observed an impaired IFNgamma production on IL-2 receptor activation.

24 ermore, PGE2 downregulated the expression of IL-2 receptor alpha (CD25).

25 ed a child born with a genetic deficiency of IL-2 receptor alpha (IL-2Ralpha, CD25) expression who ha

26 Ab)-mediated inhibition of the high-affinity IL-2 receptor alpha (IL-2Ralpha/CD25) during immunothera

27 a), interleukin 3 (IL-3), IL-4, IL-5, IL-13, IL-2 receptor alpha (IL-2Ralpha; CD25), CD40L, and macro

28 eas STAT5 phosphorylation and DNA binding to IL-2 receptor alpha (IL2RA) are reduced or not affected

29 ow that an MS-associated polymorphism in the IL-2 receptor alpha (IL2RA) gene specifically increases

30 d IPEX-like disorders caused by mutations in IL-2 receptor alpha (IL2RA), signal transducer and activ

31 Elevated serum levels of the soluble form of IL-2 receptor alpha (sIL-2Ralpha) have been correlated w

32 d from that of the antibody by using an anti-IL-2 receptor alpha antibody single chain Fv-streptavidi

33 s) are characterized by a high expression of IL-2 receptor alpha chain (CD25) and of forkhead box P3

34 Interleukin 2 (IL-2) signaling through the IL-2 receptor alpha chain (CD25) facilitates HIV replica

35 n of these cells is associated with impaired IL-2 receptor alpha chain (CD25) gene and cell surface e

36 ppressed the expression of the high affinity IL-2 receptor alpha chain (CD25) on virus-specific CD4 T

37 rotein A repetitions predominant (GARP), the IL-2 receptor alpha chain (CD25), and programmed cell de

38 xpression on CD8(+) T cells of high-affinity IL-2 receptor alpha chain (CD25), costimulatory molecule

39 ted defective IL-2-induced expression of the IL-2 receptor alpha chain (IL-2R alpha), a protein that

40 IL-12 stimulated increases in IL-2 receptor alpha chain gene (CD25) mRNA levels and su

41 CD8(+) T cells can account for the impaired IL-2 receptor alpha chain gene expression.

42 age colony-stimulating factor (GM-CSF ), and IL-2 receptor alpha chain gene.

43 Serum soluble IL-2 receptor alpha chain levels and in vitro immunoglob

44 ductions in interleukin (IL)-2 secretion and IL-2 receptor alpha chain mRNA transcription, suggesting

45 egulated programmed death-1 (PD-1) and CD25 (IL-2 receptor alpha chain), and led to antigen-specific

46 s of immune dysregulation, including soluble IL-2 receptor alpha chain, CD45RO(+)CD4(+) effector T ce

47 ransduced cells had higher expression of the IL-2 receptor alpha chain, DN Ikaros-transduced cells ac

48 ptide corresponding to residues 61-73 of the IL-2 receptor alpha chain.

49 tional expression of CD25, the high affinity IL-2 receptor alpha chain.

50 ient in interleukin (IL)-2 production or the IL-2 receptor alpha or beta chains develop a lethal auto

51 find a reduced pH sensitivity of binding to IL-2 receptor alpha relative to IL-2 receptor beta compa

52 The scientific basis for the choice of the IL-2 receptor alpha subunit as a target for monoclonal a

53 he anti-human Tac monoclonal antibody to the IL-2 receptor alpha subunit fused to a 38-kDa fragment o

54 cytoplasmic targeting sequences, such as the IL-2 receptor alpha subunit Tac.

55 We identified CD25, the IL-2 receptor alpha subunit, as a favorable target for s

56 the most informative biomarkers, followed by IL-2 receptor alpha, alpha1-antitrypsin, C-reactive prot

57 2) inhibitor, NS398, significantly increased IL-2 receptor alpha-chain (CD25) expression on phytohema

58 ls of CD44 (CD44high) and high levels of the IL-2 receptor alpha-chain (CD25high).

59 at express CD56 and CD3 antigen, and soluble IL-2 receptor alpha-chain (sIL-2R alpha) levels before t

60 ic construct consisting of the extracellular IL-2 receptor alpha-chain and the cytoplasmic ADAM15 dom

61 e entire Ag-specific population up-regulated IL-2 receptor alpha-chain expression, underwent blast tr

62 , but the peak of expression occurred before IL-2 receptor alpha-chain up-regulation, and only a mino

63 ency of naive CD4 T cells that express CD25 (IL-2 receptor alpha-chain) increases with age on subsets

64 cing membrane and soluble forms of CD25, the IL-2 receptor alpha-chain, and quenching T-cell-derived

65 MBPp85-99 TCR transcripts were present in IL-2 receptor alpha-positive T cells which were induced

66 in 15- to 30-fold increased affinity for the IL-2 receptor alpha-subunit (IL-2Ralpha).

67 es that express IL-15 receptor alpha but not IL-2 receptor alpha.

68 receptor beta/gamma heterodimer (but not the IL-2 receptor alpha/beta/gamma complex) have the potenti

69 rface expression of the human interleukin-2 (IL-2) receptor alpha (IL2RA, or CD25) protein are restri

70 CD25, the high-affinity interleukin-2 (IL-2) receptor alpha chain, is rapidly upregulated by an

71 Interleukin-2 (IL-2) receptor alpha knockout (IL-2Ralpha(-/-)) mice hav

72 to reduced expression of the interleukin-2 (IL-2) receptor alpha subunit CD25, accumulation of Foxp3

73 ely express the high-affinity interleukin 2 (IL-2) receptor alpha-chain (CD25); however, the precise

74 D69 but not the high-affinity interleukin 2 (IL-2) receptor alpha-chain CD25 and produce gamma interf

75 ct in the expression of CD25 (interleukin-2 [IL-2] receptor alpha chain) on Ad5-elicited CD4 T cells,

76 n, the latter by promoting endocytic loss of IL-2 receptor-alpha (CD25).

77 n of CD56+CD3- cells and an up-regulation of IL-2 receptor-alpha expression on natural killer cells.

78 determined the prognostic relevance of CD25 (IL-2 receptor-alpha) expression in 657 patients (</= 60

79 sly validated diagnostic biomarkers of GVHD (IL-2 receptor-alpha; tumor necrosis factor receptor-1; h

80 h significantly increased serum interleukin (IL)-2 receptor and IL-12 levels, which is consistent wit

81 oliferation by enhancing signals through the IL-2 receptor and by other mechanisms independent of the

82 hanism of inhibition involved suppression of IL-2 receptor and Jak3 expression.

83 y these migrants sustained expression of the IL-2 receptor and promoted delayed type hypersensitivity

84 tial stages of G1, including upregulation of IL-2 receptor and synthesis of IL-2.

85 ary, costimulation of human NK cells via the IL-2 receptor and the IL-12 receptor induces significant

86 ylation of STAT3 and STAT5 downstream of the IL-2 receptor and upregulation of T-bet expression.

87 Antibodies against the gamma chain of the IL-2 receptor and, to a lesser extent, against the beta

88 8(+)CD18(bright) T cells expressed IL-12 and IL-2 receptors and adhesion/costimulatory molecules to a

89 (IL-2Ralpha) is a component of high affinity IL-2 receptors and thus critically regulates T cell grow

90 alpha) chain is a component of high-affinity IL-2 receptors and thus is a key regulator of lymphocyte

91 fies the alpha subunit of the interleukin-2 (IL-2) receptor and blocks the interaction of this cytoki

92 with the common chain of the interleukin-2 (IL-2) receptor and is involved in the function of the re

93 ight deficiencies in both the interleukin-2 (IL-2) receptor and its downstream signaling pathway as a

94 y expresses the high-affinity interleukin 2 (IL-2) receptor and produces immunoregulatory cytokines.

95 ndent upon TCR engagement with MHC class II, IL-2 receptor, and Akt signaling, but not upon costimula

96 e increased expression of the interleukin-2 (IL-2) receptor, and combination with the IL-2 toxin conj

97 e compared with those receiving interleukin (IL)-2-receptor antagonists (n=217) or antithymocyte glob

98 ilar in patients induced with alemtuzumab or IL-2 receptor antagonists.

99 and repeated after the addition of the anti-IL-2 receptor (anti-CD25) monoclonal antibody, basilixim

100 (group 3; n = 43); and CITR recipients given IL-2 receptor antibodies (IL-2RAb) alone (group 4; n = 1

101 splantation and the use of anti-interleukin (IL)-2 receptor antibody as a maintenance immunosuppressa

102 yte, polyclonal antilymphocyte, interleukin (IL)-2 receptor antibody, or no induction therapy in prim

103 immunosuppressive therapy using interleukin (IL)-2 receptor antibody, tacrolimus, mycophenolate mofet

104 Determine the impact of cytolytic versus IL-2 receptor antibody (IL-2RA) induction on acute rejec

105 Use of anti-IL-2 receptor antibody as a part of maintenance immunosu

106 The addition of humanized IL-2 receptor antibody daclizumab (DZB) to CsA-based imm

107 olate mofetil (MMF), sirolimus, and the anti-IL-2 receptor antibody daclizumab consistently resulted

108 Among induction therapies, IL-2 receptor antibody induction was associated with the

109 cells was performed with injections of anti-IL-2 receptor antibody into the mice.

110 ptor, conferred cell-spreading capability on IL-2 receptor antibody substrates.

111 Anti-IL-2 receptor antibody therapy, given intravenously with

112 e in AR from 75% to 44% with the use of anti-IL-2 receptor antibody therapy.

113 From 2008 onwards (second era), monthly anti-IL-2 receptor antibody was added to the maintenance immu

114 IL-2 receptor antibody was associated with a 17% reduced

115 signaling by calcineurin inhibition or anti-IL-2 receptor-antibody blockade.

116 zation kinetics of 2D1 via the high affinity IL-2 receptor are equivalent to those of WT but that a s

117 Dysregulation of the IL-2-IL-2 receptor axis is associated with aberrant Foxp3(+)T

118 that diverge in response to signals from the IL-2 receptor, Bcl6, and B cells.

119 cosal EG2+ (activated eosinophils) or CD25+ (IL-2-receptor-bearing) cells, nor did they decrease the

120 lineage conversion in CLPs are delivered via IL-2 receptor beta (IL-2R beta) intracellular domains.

121 mple, Jak1 and Jak3 bind specifically to the IL-2 receptor beta (IL-2Rbeta) and common gamma (gammac)

122 n-2 (IL-2) induces heterodimerization of the IL-2 receptor beta (IL-2Rbeta) and gammac chains of its

123 ransfected with the cDNA for the full-length IL-2 receptor beta (IL-2Rbeta) and gammac chains, compon

124 ntroducing wild-type and mutant forms of the IL-2 receptor beta (IL-2Rbeta) chain that lacked specifi

125 growth by exogenous IL-2, which binds to the IL-2 receptor beta (IL-2Rbeta) chain ubiquitously expres

126 -8), monocyte chemotactic protein 3 (MCP-3), IL-2 receptor beta (IL-2Rbeta), IL-15 receptor alpha (IL

127 Common to both cytokine receptors, the IL-2 receptor beta (IL2Rbeta) chain is selectively maint

128 E5 in transformation, as well as bind to the IL-2 receptor beta and gamma chains and the H+ vacuolar

129 receptor (NILR), that is most related to the IL-2 receptor beta chain (IL-2Rbeta) and physically adja

130 now have found that tyrosine residues in the IL-2 receptor beta chain (IL-2Rbeta) are unexpectedly no

131 n of intracellular substrates, including the IL-2 receptor beta chain (IL-2Rbeta), Janus kinase 1 (Ja

132 ) receptor beta common chain (betac) and the IL-2 receptor beta chain (IL-2Rbeta), lack such sites, l

133 ly explained by diminished expression of the IL-2 receptor beta chain (IL-2Rbeta), which is a compone

134 demonstrate that CIS also interacts with the IL-2 receptor beta chain (IL-2Rbeta).

135 ion was markedly enhanced by the presence of IL-2 receptor beta chain (IL-2Rbeta).

136 receptor (IL-21R) is closely related to the IL-2 receptor beta chain and is capable of transducing s

137 t on the coexpression of Jak3 along with the IL-2 receptor beta chain and the common cytokine recepto

138 of the chimeric JAK3-JAK2 protein, JAK1, the IL-2 receptor beta chain, and signal transducer and acti

139 h an activated phenotype, phenotypes seen in IL-2 receptor beta chain-deficient mice.

140 s largely dependent upon tyrosine 338 of the IL-2 receptor beta chain.

141 f binding to IL-2 receptor alpha relative to IL-2 receptor beta compared with WT, which could be resp

142 The IL-2 receptor beta subunit (IL-2Rbeta) serves in this ca

143 ng specificity for IL-2 or IL-15, and shared IL-2 receptor beta- and gamma-chains.

144 the common gamma chain (gammac) and through IL-2 receptor beta-chain (CD122) subunits, they direct d

145 The interleukin-2 IL-2 receptor beta-chain (IL-2Rbeta) is an essential com

146 T cells by their expression of the signaling IL-2 receptor beta-chain CD122, forming with common gamm

147 pression of cell surface receptors including IL-2 receptor beta.

148 nant interleukin engineered to stimulate the IL-2 receptor beta/gamma heterodimer (but not the IL-2 r

149 Its interaction with the interleukin-2 (IL-2) receptor beta- and gamma-chains implies an involve

150 r of Il2rb, which encodes the interleukin 2 (IL-2) receptor beta-chain, and controlled the responsive

151 ent spleens, mRNAs were low for interleukin (IL)-2 receptor-beta, interferon regulatory factor-1, and

152 at compounds bound reversibly to IL-2 at the IL-2 receptor binding site.

153 teroids in individuals with severe AH and if IL-2 receptor blockade can reverse this.

154 IL-2 receptor blockade represents a possible mechanism t

155 IL-2-receptor blockade is effective for preventing allor

156 idence interval [CI] 1.10-1.43, P=0.001) and IL-2 receptor blocker (n=1396, HR 1.19, 95% CI 1.01-1.39

157 When compared with alemtuzumab and IL-2 receptor blocker, r-ATG induction seems to be assoc

158 n (r-ATG), alemtuzumab, or an interleukin-2 (IL-2) receptor blocker and were discharged on a calcineu

159 Gene expression of IL-2 and IL-2 receptors (both alpha and beta) and binding of NF-k

160 system that does not share elements with the IL-2 receptor but uses a novel 60- to 65-kDa IL-15RX sub

161 t levels of the alpha subunit of the soluble IL-2 receptor, but not IFN-gamma, are elevated in the se

162 cancer was shown to express the interleukin (IL)-2 receptor by an immunohistochemical assay for the p

163 oantigen-specific T suppressor cells express IL-2 receptor (CD25) and that IL-2 in part promotes thei

164 th decreased expression of the high affinity IL-2 receptor (CD25).

165 erapy using the chimeric anti-interleukin-2 (IL-2) receptor (CD25) monoclonal antibody (mAb) basilixi

166 ferences between cell lines were observed in IL-2 receptor chain (alpha, beta, or gamma(c)) expressio

167 ing was performed to study expression of the IL-2 receptor chains on T lymphocytes and natural killer

168 The response is induced via IL-2 receptor common gamma chain cytokines and a Janus k

169 t allowed for coexpression of MDR1 and human IL-2 receptor common gamma-chain cDNAs.

170 r) kinase associated with the interleukin-2 (IL-2) receptor common gamma chain (gamma(c)) that is act

171 of a targeted mutation in the interleukin 2 (IL-2) receptor common gamma chain (IL2rg(null)) into mic

172 three chains (CD25, CD122, and CD132) of the IL-2 receptor complex and are dependent on IL-2 for surv

173 cells, SOCS-3 was able to interact with the IL-2 receptor complex, and in particular tyrosine phosph

174 t IL-2 induces association of SHP-1 with the IL-2 receptor complex, and that once SHP-1 is recruited

175 ent of the tyrosine phosphatase TCPTP to the IL-2 receptor complex, which resulted in dephosphorylati

176 rum levels of the soluble alpha chain of the IL-2 receptor complex.

177 ignaling by IL-4, IL-7, and IL-15, which use IL-2 receptor components, also was inhibited, indicating

178 2 did not result in dephosphorylation of the IL-2 receptor components.

179 usion of the cytosolic domain of TEM8 to the IL-2 receptor, conferred cell-spreading capability on IL

180 ed IL-2, acting through the NK high-affinity IL-2 receptor, costimulates CD56(bright) NK cells to sec

181 y in which T cells lacking the high-affinity IL-2 receptor could be studied in an otherwise healthy m

182 onoclonal antibody against the high-affinity IL-2 receptor (daclizumab) was performed in 70 adult, ca

183 The use of IL-2- or IL-2-receptor-deficient mice is problematic owing to the

184 oduced Th1 memory cells in an interleukin-2 (IL-2) receptor-dependent fashion.

185 bodies that recognize the alpha chain of the IL-2 receptor (e.g. daclizumab) have been used to preven

186 ucture of the trimeric assembly of the human IL-2 receptor ectodomains in complex with IL-2 at 3.0 A

187 r blockade of the high-affinity interleukin (IL)-2 receptor effectively prevented T-cell alloreactivi

188 noclonal antibody against the interleukin 2 (IL-2) receptor expressed on activated T lymphocytes.

189 in showed antitumor effects in patients with IL-2 receptor expressing CTCL and NHL.

190 We have previously shown that interleukin (IL)-2 receptor-expressing lymphoid cells stimulated with

191 -2]), a recombinant fusion protein targeting IL-2 receptor-expressing malignant T lymphocytes, in pat

192 the CD70(+)CD8(+) T cells that up-regulated IL-2 receptor expression but did not occur in CD70(-)CD8

193 y IL-2 in G(1) with no appreciable effect on IL-2 receptor expression in a manner similar to that of

194 es, rhIL-2 increased viral protein (p24) and IL-2 receptor expression in isolated B lymphocytes from

195 T cell proliferation associated with reduced IL-2 receptor expression, but operating independently of

196 tion of PBMC proliferation and a decrease in IL-2 receptor expression.

197 Loss of interleukin-7 (IL-2) receptor expression has been described in T lympho

198 In this study, we tested interleukin-2 (IL-2) receptor expression, IL-2-mediated proliferation,

199 t containing the non-adhesive interleukin-2 (IL-2) receptor extracellular domain and the VE-cadherin

200 racellular domains of the Tac subunit of the IL-2 receptor, fused to the cytoplasmic domain of beta(1

201 ptor alpha (IL-4Ralpha)-chain but not to the IL-2 receptor gamma (IL-2Rgamma)-chain.

202 mutations in IL-7 receptor alpha (IL7RA) and IL-2 receptor gamma (IL2RG) were observed at the most im

203 recombination activating gene 1/2 (RAG 1/2), IL-2 receptor gamma (IL2RG), and zeta chain-associated p

204 kins 9 (IL-9) and 4 are cytokines within the IL-2 receptor gamma chain (IL-2R gamma) superfamily that

205 seen in immunodeficient patients lacking the IL-2 receptor gamma chain or Jak3.

206 afted at a markedly higher level in NOD/SCID/IL-2 receptor gamma chain-null (NSG) mice compared with

207 The IL-2 receptor gamma common (IL-2Rgammac) chain is the sh

208 s, patients with the p.R222C mutation in the IL-2 receptor gamma(IL2RG) gene as well as IL-10 recepto

209 cells in NOD-SCID gamma (with interleukin-2 (IL-2) receptor gamma chain deficiency) mice also reveale

210 intestinal compartment in humanized NOD/SCID/IL-2 receptor-gamma(null) (NSG) mice.

211 l growth factors (TCGFs), utilize the common IL-2 receptor gammac chain as a critical signaling compo

212 The IL-10 receptor and the IL-2 receptor gammac chain were almost equally expressed

213 cyte-macrophage colony-stimulating factor or IL-2 receptor genes.

214 hanisms for the recruitment of PI 3-K to the IL-2 receptor have been proposed.

215 -cadherin tail was fused to the interleukin (IL)-2 receptor (IL-2R) extracellular domain.

216 IV-1) replication in activated, interleukin (IL)-2 receptor (IL-2R)-expressing human peripheral blood

217 cell lines screened constitutively expressed IL-2 receptor (IL-2R) and IL-4R genes.

218 r the contribution of the interleukin (IL)-2/IL-2 receptor (IL-2R) autocrine pathway.

219 lymphoma cells expressing the high-affinity IL-2 receptor (IL-2R) consisting of the alpha/p55/CD25,

220 together comprise the intermediate affinity IL-2 receptor (IL-2R) expressed on the surface of restin

221 ival mechanisms, none of the 3 chains of the IL-2 receptor (IL-2R) expresses a binding site for PI 3-

222 ed accumulation of T cell receptor (TCR) and IL-2 receptor (IL-2R) mediated signaling events that pro

223 ns, multiple genes in the interleukin (IL)-2/IL-2 receptor (IL-2R) pathway are associated with type 1

224 ct, exhibited significantly higher levels of IL-2 receptor (IL-2R) signaling compared with those in l

225 amma c could be functionally replaced in the IL-2 receptor (IL-2R) signaling complex by a severely tr

226 f transcription (STAT)5, which are linked to IL-2 receptor (IL-2R) signaling pathway, were not affect

227 ell as proliferation, making unclear whether IL-2 receptor (IL-2R) signals ultimately have a predomin

228 f altered interleukin-2 (IL-2) secretion and IL-2 receptor (IL-2R)-signal transducer and activator of

229 60 nM inhibitor of the interleukin-2 (IL-2)/IL-2 receptor (IL-2Ralpha) interaction.

230 The interleukin-2 (IL-2) receptor (IL-2R) is composed of three subunits.

231 ors, which share the common gamma chain with IL-2 receptors, IL-7 cannot initiate lineage conversion

232 The gene encoding the alpha-chain of the IL-2 receptor, IL2RA, harbors alleles associated with ri

233 ate with the levels of a soluble form of the IL-2 receptor in subjects with type 1 diabetes and multi

234 We previously showed that the IL-2 receptor induces expression of cyclin D2 by activat

235 htheria toxin and ligand, IL-2, binds to the IL-2 receptor, is internalized, and causes cell death.

236 on IL-2 activity in that it was not seen in IL-2 receptor knockout mice, while PspA in alum induced

237 he IL-2 molecule alter interactions with the IL-2 receptor, leading to differential cellular targetin

238 ted a clear correlation between interleukin (IL) 2 receptor levels and immunological events after tra

239 ase elevation correlated with plasma soluble IL-2 receptor levels and not with viremia levels.

240 correlates including ch14.18 levels, soluble IL-2 receptor levels, and human antichimeric antibody (H

241 ntial therapeutic activity of humanized anti-IL-2 receptor mAb (Daclizumab) therapy in the treatment

242 CsA and anti-IL-2 receptor mAb are drugs that reduce cytokine synthes

243 This is the first study to combine an anti-IL-2 receptor mAb with a drug from the rapamycin class p

244 monoclonal antibody (mAb) basiliximab (anti-IL-2 receptor mAb) for induction therapy (basiliximab: 5

245 (e.g., IL-15) that are not inhibited by anti-IL-2 receptor mAb.

246 es and that the alpha subunit of the soluble IL-2 receptor may serve as a biomarker of disease progre

247 Introduction of Pax5 blocks ectopic IL-2 receptor-mediated myeloid lineage conversion in CLP

248 ults indicate that TCR-CD3/CD28-mediated and IL-2 receptor-mediated signals converge at the level of

249 orylation plays a key role in interleukin-2 (IL-2) receptor-mediated activation of Janus tyrosine kin

250 eg cells the expression of the high-affinity IL-2 receptor, needed for STAT5-dependent survival of Tr

251 we sought to dissect the effects of CD28 and IL-2 receptor pathways on cell cycle progression and det

252 The interleukin-2 (IL-2) receptor promotes T cell proliferation in part by

253 r, to be crucially regulated by interleukin (IL)-2 receptor (R) signals.

254 temporal expression of the cytokine-specific IL-2 receptor (R) alpha and IL-7Ralpha chains.

255 the beta and common gamma(c) subunits of the IL-2 receptor (R) as a heterodimer with intermediate aff

256 2 secretion and subsequent signaling via the IL-2 receptor, recent studies indicate that the dramatic

257 Therapeutic immune modulation of IL-2 receptor restores impaired immune regulation in MS

258 Analysis of mutants of the beta-chain of the IL-2 receptor revealed that the granulocyte- and monocyt

259 ets the STAT5 signaling pathway to attenuate IL-2 receptor signal transduction in human T cells.

260 IV gp120-derivatives attenuates interleukin (IL)-2 receptor signaling.

261 We demonstrate that CARMA1 regulates IL-2 receptor signaling and controls the IL-2-stimulated

262 ly redundant pathways exist for formation of IL-2 receptor signaling complexes, suggesting a more com

263 c memory cells which is primarily favored by IL-2 receptor signaling during ex vivo generation of the

264 Consistent with this, sustained IL-2 receptor signaling during expansion drove terminal-

265 m lymphoid to myeloid in response to ectopic IL-2 receptor signaling in human IL-2Rbeta transgenic mi

266 tion of IFNgamma, in addition to a defective IL-2 receptor signaling machinery and a defective commun

267 In addition, timely blockade of IL-2 receptor signaling selectively inhibits the product

268 ires TCR-induced early GATA-3 expression and IL-2 receptor signaling, both of which are controlled by

269 cytoskeleton, resulting in amplification of IL-2 receptor signaling, enhanced CD122/CD132 colocaliza

270 ted IL-2-induced proliferation by uncoupling IL-2 receptor signaling, inhibiting phosphorylation of t

271 that rapamycin (RAPA), a drug that disrupts IL-2 receptor signaling, reduces CCR5 surface expression

272 , confirming PTEN as a negative regulator of IL-2 receptor signaling.

273 ation involves both NF-kappaB activation and IL-2 receptor signaling.

274 ven TCR signals combined with interleukin 2 (IL-2) receptor signalling.

275 reatment were analyzed for levels of soluble IL-2 receptor (sIL-2R).

276 , IL-6 (p = .073), IL-10 (p = .013), soluble IL-2 receptor (sIL-2R; p < .001), sIL-6R (p = .021), tum

277 Levels of soluble IL-2 receptors (sIL-2R) are elevated in psychiatric diso

278 aying binding affinity to the heterotrimeric IL-2 receptor similar to that of wild-type IL-2 (WT) had

279 tokine surface receptors, IL-9R alpha-chain, IL-2 receptor ss-chain, and erythropoietin receptor, can

280 s is explained by their higher expression of IL-2 receptor subunit alpha (IL-2Ralpha) and gamma chain

281 ice and mice lacking the beta-subunit of the IL-2 receptor suggest that there is an unexpected connec

282 ted with blocking antibodies to IL-2 and the IL-2 receptor, suggesting a possible BCL6-STAT5 binding

283 These insights concerning the IL-2/IL-2 receptor system facilitated the development of effe

284 eveal a previously unknown mechanism for the IL-2 receptor system in DC-mediated activation of T cell

285 Here, we mainly focus on the IL2-/IL-2 receptor system, as it is one of the best-studied s

286 several methods, including their binding to IL-2 receptors, T-cell proliferation assays, the inducti

287 tant negative regulator of signaling via the IL-2 receptor that affects the development of Treg cells

288 inhibits up-regulation of the high-affinity IL-2 receptor that is necessary for T(CD8) survival.

289 cytokines including CCL5, G-CSF, and soluble IL-2 receptor, that were significantly elevated in WM pa

290 of one of the two signalling subunits of the IL-2 receptor, the beta chain (CD122) (mean decrease = 5

291 ese initial findings would suggest that anti-IL-2 receptor therapy may be an effective therapeutic ap

292 tion of Gab2 may be important in linking the IL-2 receptor to activation of MAPK and may be an import

293 ta revealed that Janus kinases (JAKs) couple IL-2 receptors to the coordinated phosphorylation of tra

294 pression of the beta and gamma chains of the IL-2 receptor was detected in the IL-2 group.

295 that of IL-2 when the intermediate-affinity IL-2 receptor was expressed.

296 (+) T cell model using wild-type and mutated IL-2 receptors, we examined the effects of TGF-beta on d

297 gamma-inducible alpha subunit of the soluble IL-2 receptor were elevated in serum and bronchoalveolar

298 [TNF]-alpha, interleukin [IL]-6 and soluble IL-2 receptor) were investigated.

299 tion leads to the formation of high affinity IL-2 receptors when IL-2Ralpha is co-expressed with the

300 ng selective saturation of the high affinity IL-2 receptor, while the peak SCF serum concentration wa